ACPAs, routinely detected using the anti-cyclic citrullinated peptide (anti-CCP) test (5), are often present years before clinically overt disease (6), and anti-CCP-positive RA patients have a worse prognosis with a higher degree of erosive damage than anti-CPP-negative RA patients (7). The gene discussed is CPP; the disease is rheumatoid arthritis.